Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Antibody display technologies from phages to cells: translational bottlenecks and AI-enabled opportunities
by
Das, Punyatoya
, Das, Rohit
, Arumugam, Somasundaram
, Sreedhar, Remya
, Sahu, Amrita
, Mohan, Utpal
, Bhattacharya, Indrajit
, Bhattacharya, Teeshyo
in
antibody library
/ Antigens
/ Artificial intelligence
/ artificial intelligence (AI)
/ Bone marrow
/ Cells
/ display technology
/ Epitope mapping
/ FDA approval
/ Flow cytometry
/ Genes
/ Glycosylation
/ Good Manufacturing Practice
/ Immune response
/ Manufacturing
/ Medical innovations
/ Medical research
/ Microfluidics
/ Monoclonal antibodies
/ monoclonal antibody
/ Multiple myeloma
/ Peptide mapping
/ phage
/ Proteins
/ Review
/ Technology
2026
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Antibody display technologies from phages to cells: translational bottlenecks and AI-enabled opportunities
by
Das, Punyatoya
, Das, Rohit
, Arumugam, Somasundaram
, Sreedhar, Remya
, Sahu, Amrita
, Mohan, Utpal
, Bhattacharya, Indrajit
, Bhattacharya, Teeshyo
in
antibody library
/ Antigens
/ Artificial intelligence
/ artificial intelligence (AI)
/ Bone marrow
/ Cells
/ display technology
/ Epitope mapping
/ FDA approval
/ Flow cytometry
/ Genes
/ Glycosylation
/ Good Manufacturing Practice
/ Immune response
/ Manufacturing
/ Medical innovations
/ Medical research
/ Microfluidics
/ Monoclonal antibodies
/ monoclonal antibody
/ Multiple myeloma
/ Peptide mapping
/ phage
/ Proteins
/ Review
/ Technology
2026
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Antibody display technologies from phages to cells: translational bottlenecks and AI-enabled opportunities
by
Das, Punyatoya
, Das, Rohit
, Arumugam, Somasundaram
, Sreedhar, Remya
, Sahu, Amrita
, Mohan, Utpal
, Bhattacharya, Indrajit
, Bhattacharya, Teeshyo
in
antibody library
/ Antigens
/ Artificial intelligence
/ artificial intelligence (AI)
/ Bone marrow
/ Cells
/ display technology
/ Epitope mapping
/ FDA approval
/ Flow cytometry
/ Genes
/ Glycosylation
/ Good Manufacturing Practice
/ Immune response
/ Manufacturing
/ Medical innovations
/ Medical research
/ Microfluidics
/ Monoclonal antibodies
/ monoclonal antibody
/ Multiple myeloma
/ Peptide mapping
/ phage
/ Proteins
/ Review
/ Technology
2026
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Antibody display technologies from phages to cells: translational bottlenecks and AI-enabled opportunities
Journal Article
Antibody display technologies from phages to cells: translational bottlenecks and AI-enabled opportunities
2026
Request Book From Autostore
and Choose the Collection Method
Overview
Beginning with the pioneering hybridoma technology developed in 1975, antibody generation methodologies have advanced substantially, culminating in today’s single-cell techniques. Each successive approach contributes unique applications, advantages, and drawbacks that reflect the field’s dynamic progress. We highlight the impact of integrating single-cell RNA sequencing (scRNA-seq) with display technologies. This holds potential for the healthcare industry by enabling efficient identification and development of diagnostic and therapeutic antibodies. Monoclonal antibodies (MAbs) produced via each major technology are discussed to illustrate practical outcomes. We have also explored the essential role of glycosylation in maintaining antibody stability and function. Furthermore, we discussed single-cell RNA sequencing (scRNA-seq) that enables high-resolution profiling of immune repertoires and tumour heterogeneity, facilitating the identification of antigen-specific antibodies and rare cell populations. Integration with microfluidics and computational analysis enhances biomarker discovery and cell-specific resolution. These advances support personalised therapies and accelerate next-generation antibody discovery. Finally, we address the emerging integration of machine learning and artificial intelligence in antibody discovery, emphasising recent advances in epitope mapping and predicting three-dimensional protein structures from primary amino acid sequences. Collectively, these developments are poised to revolutionise antibody engineering and expand its impact on therapeutic innovation.
This website uses cookies to ensure you get the best experience on our website.